Otonomy is a biopharmaceutical company focused on the development of innovative therapeutics for neurotology. Co. developed the application of drug delivery technology to the ear. Co.'s primary focus is on the development of three programs in its pipeline: OTO-313 in Phase 2 for tinnitus; OTO-413 in Phase 2a for hearing loss; and OTO-825, a gene therapy for congenital hearing loss, in investigational new drug (IND)-enabling activities. Additionally, Co. is conducting preclinical development of OTO-510 for otoprotection and OTO-6XX for severe hearing loss. The OTIC average annual return since 2014 is shown above.
The Average Annual Return on the OTIC average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether OTIC average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OTIC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|